Tag Archives: Digital Health

Apple Watch detects irregular heart beat in large U.S. study

apple_watch(Reuters) – The Apple Watch was able to detect irregular heart pulse rates that could signal the need for further monitoring for a serious heart rhythm problem, according to data from a large study funded by Apple Inc (AAPL.O), demonstrating a potential future role for wearable consumer technology in healthcare.

Researchers hope the technology can assist in early detection of atrial fibrillation, the most common form of irregular heart beat. Patients with untreated AF are five times more likely to have a stroke.

Click here for more…

Using Machine Learning to develop blood test for key Alzheimer’s biomarker

giornata-mondiale-alzheimer-2018-824-464Alzheimer’s disease, a terminal neurodegenerative disease, has historically been diagnosed based on observing significant memory loss. Recent research has shown that a biological marker associated with the disease, a peptide called amyloid-beta, changes long before any memory-related issues are apparent.

Examining the concentration of the peptide in an individual’s spinal fluid provides an indication of risk decades before any memory related issues occur. Unfortunately, accessing spinal fluid is highly invasive, requires an anaesthetist and is expensive to conduct on large segments of the population. Hence, there is a strong effort in the research community to develop a less invasive test, such as a blood test, that can yield information about Alzheimer’s disease risk.

A recent paper by my team at IBM Research – Australia, published today in Scientific Reports, used machine learning to identify a set of proteins in blood that can predict the concentration of amyloid-beta in spinal fluid. The models we built could one day help clinicians to predict this risk with an accuracy of up to 77%.

Click here for more…

Scientific ReportsA blood-based signature of cerebrospinal fluid Aβ1–42 status (Published: 11 March 2019)

Digital Healthcare growth drivers in 2019

Digital HealthcareThe US Food and Drug Administration (#FDA) has cautiously moved to embrace Digital Therapeutics, mobile trial platforms and expanded use of real world evidence (#RWE) mining for clinical development: this progress will continue to drive sponsor investment.

Substantively, the agency has issued landmark approvals of digital products including Pear’s reSET, Proteus/Otsuka’s Abilify MyCite, and earlier WellDoc’s BlueStar.

The list of companies with digital products in development that will be seeking approval is growing.

Click here for more…